PYC Raising up to $653m to Deliver Human Efficacy Data
Filed with ASX · · 8 pages · English
• The Company today announces that it is raising up to ~$653m to support progression of four drug candidates with disease-modifying potential through critical human efficacy read-outs2 • The fundraising consists of an equity issue comprising: o $128m placement to leading US specialist life sciences investors led by RA Capital Management and including Perceptive Advisors, Driehaus Capital Managemen
PYC Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from PYC Therapeutics
- PYC Capital Raising Presentation
- Trading Halt
- Quarterly Activities/Appendix 4C Cash Flow Report
- PKD Clinical Trial - Safety Outcomes in Part A
- Sustained Vision Improvement in RP11 Patients
Later from PYC Therapeutics
- Completion of Placement and Institutional Entitlement Offer
- Retail Offer Booklet
- Half Yearly Report and Accounts
- PKD Clinical Trial - Approval to Escalate Dosing
- Completion of Retail Entitlement Offer
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics